JP2020501531A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020501531A5 JP2020501531A5 JP2019527232A JP2019527232A JP2020501531A5 JP 2020501531 A5 JP2020501531 A5 JP 2020501531A5 JP 2019527232 A JP2019527232 A JP 2019527232A JP 2019527232 A JP2019527232 A JP 2019527232A JP 2020501531 A5 JP2020501531 A5 JP 2020501531A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding fragment
- seq
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims 34
- 239000000427 antigen Substances 0.000 claims 31
- 102000036639 antigens Human genes 0.000 claims 31
- 108091007433 antigens Proteins 0.000 claims 31
- 125000003275 alpha amino acid group Chemical group 0.000 claims 20
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 13
- 230000035772 mutation Effects 0.000 claims 13
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 10
- 150000001413 amino acids Chemical class 0.000 claims 7
- 210000004027 cell Anatomy 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 150000007523 nucleic acids Chemical class 0.000 claims 5
- 108091035707 Consensus sequence Proteins 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 231100000433 cytotoxic Toxicity 0.000 claims 3
- 230000001472 cytotoxic effect Effects 0.000 claims 3
- 102000050327 human TNFRSF9 Human genes 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 claims 2
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims 2
- 102000009109 Fc receptors Human genes 0.000 claims 2
- 108010087819 Fc receptors Proteins 0.000 claims 2
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 2
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 238000002648 combination therapy Methods 0.000 claims 2
- 230000009827 complement-dependent cellular cytotoxicity Effects 0.000 claims 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000013598 vector Substances 0.000 claims 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 1
- 206010061692 Benign muscle neoplasm Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010005949 Bone cancer Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 229940116741 CD137 agonist Drugs 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 102000018297 Immunoglobulin subtype Human genes 0.000 claims 1
- 108050007411 Immunoglobulin subtype Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 241000282567 Macaca fascicularis Species 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 201000004458 Myoma Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 230000000112 colonic effect Effects 0.000 claims 1
- 238000004132 cross linking Methods 0.000 claims 1
- 230000009260 cross reactivity Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000007246 mechanism Effects 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 206010038038 rectal cancer Diseases 0.000 claims 1
- 201000001275 rectum cancer Diseases 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1619648.7 | 2016-11-21 | ||
| GBGB1619648.7A GB201619648D0 (en) | 2016-11-21 | 2016-11-21 | Novel antibodies and uses thereof |
| PCT/EP2017/079930 WO2018091740A2 (en) | 2016-11-21 | 2017-11-21 | Novel antibodies and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020501531A JP2020501531A (ja) | 2020-01-23 |
| JP2020501531A5 true JP2020501531A5 (https=) | 2020-12-17 |
| JP7068303B2 JP7068303B2 (ja) | 2022-05-16 |
Family
ID=57993708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019527232A Active JP7068303B2 (ja) | 2016-11-21 | 2017-11-21 | 新規抗ｃｄ１３７抗体およびその使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US11535678B2 (https=) |
| EP (1) | EP3541844A2 (https=) |
| JP (1) | JP7068303B2 (https=) |
| KR (1) | KR102679632B1 (https=) |
| CN (1) | CN109963873B (https=) |
| AU (1) | AU2017360094B2 (https=) |
| BR (1) | BR112019010265A2 (https=) |
| CA (1) | CA3044339A1 (https=) |
| GB (1) | GB201619648D0 (https=) |
| IL (1) | IL266738B2 (https=) |
| MX (1) | MX2019005911A (https=) |
| NZ (1) | NZ754051A (https=) |
| RU (1) | RU2019116624A (https=) |
| WO (1) | WO2018091740A2 (https=) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201811184UA (en) | 2016-06-20 | 2019-01-30 | F Star Beta Ltd | Lag -3 binding members |
| CN112210010B (zh) * | 2017-01-06 | 2023-12-05 | 优特力克斯有限公司 | 抗-人4-1bb抗体及其应用 |
| KR20240017409A (ko) | 2017-04-13 | 2024-02-07 | 아게누스 인코포레이티드 | 항-cd137 항체 및 이의 사용 방법 |
| US11512134B2 (en) | 2017-08-01 | 2022-11-29 | Eli Lilly And Company | Anti-CD137 antibodies |
| CA3071383C (en) | 2017-08-01 | 2022-04-12 | Eli Lilly And Company | Anti-cd137 antibodies |
| WO2019036855A1 (en) | 2017-08-21 | 2019-02-28 | Adagene Inc. | Anti-cd137 molecules and use thereof |
| WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
| WO2019148444A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
| JP7059388B2 (ja) | 2018-03-23 | 2022-04-25 | イーライ リリー アンド カンパニー | 抗ｐｄ－ｌ１抗体との組み合わせのための抗ｃｄ１３７抗体 |
| PT3820569T (pt) | 2018-07-12 | 2025-01-14 | Invox Pharma Ltd | Moléculas de anticorpo que se ligam a pd-l1 e cd137 |
| GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
| GB201811450D0 (en) | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
| GB201811404D0 (en) * | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
| ES3044118T3 (en) | 2018-07-12 | 2025-11-26 | Invox Pharma Ltd | Antibody molecules that bind cd137 and ox40 |
| GB201811415D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-Mesothelin Anti bodies |
| GB201811403D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Antibody molecules |
| GB201811408D0 (en) * | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
| CN112739339B (zh) | 2018-07-23 | 2024-12-27 | 海德堡医药研究有限责任公司 | 抗cd137抗体药物缀合物(adc)在同种异体细胞疗法中的用途 |
| KR102259473B1 (ko) * | 2018-08-10 | 2021-06-02 | 추가이 세이야쿠 가부시키가이샤 | 항cd137 항원 결합 분자 및 그의 사용 |
| SG11202102335YA (en) * | 2018-09-12 | 2021-04-29 | Eucure Beijing Biopharma Co Ltd | Anti-tnfrsf9 antibodies and uses thereof |
| CN120098128A (zh) | 2019-01-02 | 2025-06-06 | Qlsf生物治疗药物公司 | Cd137激动剂抗体及其用途 |
| NZ781538A (en) | 2019-04-24 | 2025-12-19 | Heidelberg Pharma Res Gmbh | Amatoxin antibody-drug conjugates and uses thereof |
| CN120441704A (zh) | 2019-06-26 | 2025-08-08 | 圆祥生技股份有限公司 | T细胞活化抗体 |
| KR20220087479A (ko) * | 2019-11-13 | 2022-06-24 | 허페이 한커맵 바이오테크놀로지 컴퍼니 리미티드 | 인간 4-1bb와 결합할 수 있는 분자 및 이의 응용 |
| IL294557A (en) | 2020-01-07 | 2022-09-01 | Univ Texas | Improved human methylthioadenosine/adenosine depleting enzyme variants for cancer therapy |
| CN115362270A (zh) | 2020-01-29 | 2022-11-18 | 得克萨斯州大学系统董事会 | Egfr/her2酪氨酸激酶抑制剂和/或her2/her3抗体在具有nrg1融合的癌症的治疗中的用途 |
| JP7777533B2 (ja) | 2020-01-29 | 2025-11-28 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | Ｎｒｇ１融合体を有するがんの治療のためのポジオチニブの使用 |
| KR20220148209A (ko) * | 2020-02-28 | 2022-11-04 | 상하이 헨리우스 바이오테크, 인크. | 항cd137 작제물 및 그 용도 |
| WO2021236658A1 (en) | 2020-05-19 | 2021-11-25 | Boehringer Ingelheim International Gmbh | Binding molecules for the treatment of cancer |
| CN113842456B (zh) * | 2020-06-28 | 2022-07-26 | 上海齐鲁制药研究中心有限公司 | 一种抗人4-1bb的单克隆抗体制剂及其用途 |
| EP4155319A4 (en) * | 2020-06-30 | 2024-06-12 | Nona Biosciences (Suzhou) Co., Ltd. | 4-1BB BINDING PROTEIN AND ITS USE |
| WO2022148413A1 (zh) * | 2021-01-08 | 2022-07-14 | 北京韩美药品有限公司 | 特异性结合4-1bb的抗体及其抗原结合片段 |
| JP2024522234A (ja) | 2021-06-18 | 2024-06-11 | アリゲーター・バイオサイエンス・アーベー | 新規な併用療法及びその使用 |
| WO2023056361A1 (en) | 2021-09-29 | 2023-04-06 | Board Of Regents, The University Of Texas System | Anti-hsp70 antibodies and therapeutic uses thereof |
| WO2023126821A1 (en) * | 2021-12-29 | 2023-07-06 | Curateq Biologics Private Limited | C1q binding assay |
| GB202210957D0 (en) | 2022-07-27 | 2022-09-07 | Alligator Bioscience Ab | Novel dosages |
| GB202210965D0 (en) | 2022-07-27 | 2022-09-07 | Alligator Bioscience Ab | Novel dosages |
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| CN119790076A (zh) * | 2022-09-22 | 2025-04-08 | 成都盛世君联生物技术有限公司 | 一种抗4-1bb纳米抗体及其制备和应用 |
| CN116162162B (zh) * | 2022-12-19 | 2025-05-27 | 首都医科大学附属北京胸科医院 | 一种大鼠抗小鼠cd137抗体或其功能性片段、工具抗体及其应用 |
| CN116041517B (zh) * | 2022-12-19 | 2025-02-25 | 首都医科大学附属北京胸科医院 | 一种抗人cd137抗体及其应用 |
| CN116271009A (zh) * | 2023-01-13 | 2023-06-23 | 深圳市乐土生物医药有限公司 | 含有CpG佐剂和4-1BB抗体的药物组合物及其用途 |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| US20250302763A1 (en) | 2024-02-22 | 2025-10-02 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| SE459005B (sv) | 1985-07-12 | 1989-05-29 | Aake Rikard Lindahl | Saett att framstaella sfaeriska polymerpartiklar |
| CA2192782C (en) | 1995-12-15 | 2008-10-14 | Nobuyuki Takechi | Production of microspheres |
| AR046094A1 (es) * | 2003-10-10 | 2005-11-23 | Bristol Myers Squibb Co | Anticuerpos completamente humanos contra 4-1bb humano |
| US9486524B2 (en) | 2006-09-01 | 2016-11-08 | Genticel | Composition for eliciting a specific CTL response, comprising a lympho-ablative compound and a molecule that contains antigenic sequences and targets professional antigen presenting cells |
| EP3183269A2 (en) * | 2014-08-22 | 2017-06-28 | Bristol-Myers Squibb Company | Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody |
| KR20180016972A (ko) * | 2015-02-22 | 2018-02-20 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Cd137에 결합하는 항체 치료제 |
| CN114181309B (zh) * | 2015-05-21 | 2024-07-30 | 鳄鱼生物科学公司 | 新型多肽 |
-
2016
- 2016-11-21 GB GBGB1619648.7A patent/GB201619648D0/en not_active Ceased
-
2017
- 2017-11-21 EP EP17811475.7A patent/EP3541844A2/en active Pending
- 2017-11-21 WO PCT/EP2017/079930 patent/WO2018091740A2/en not_active Ceased
- 2017-11-21 AU AU2017360094A patent/AU2017360094B2/en active Active
- 2017-11-21 NZ NZ754051A patent/NZ754051A/en unknown
- 2017-11-21 JP JP2019527232A patent/JP7068303B2/ja active Active
- 2017-11-21 RU RU2019116624A patent/RU2019116624A/ru unknown
- 2017-11-21 US US16/461,544 patent/US11535678B2/en active Active
- 2017-11-21 IL IL266738A patent/IL266738B2/en unknown
- 2017-11-21 CA CA3044339A patent/CA3044339A1/en active Pending
- 2017-11-21 BR BR112019010265-5A patent/BR112019010265A2/pt active Search and Examination
- 2017-11-21 KR KR1020197015905A patent/KR102679632B1/ko active Active
- 2017-11-21 CN CN201780071444.6A patent/CN109963873B/zh active Active
- 2017-11-21 MX MX2019005911A patent/MX2019005911A/es unknown
-
2019
- 2019-07-17 US US16/514,374 patent/US10689454B2/en active Active
-
2022
- 2022-11-10 US US18/054,373 patent/US12509526B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020501531A5 (https=) | ||
| CN110799539B (zh) | 抗4-1bb抗体及其制备和使用方法 | |
| RU2019116624A (ru) | Новые анти_cd137 антитела и их применение | |
| JP5723279B2 (ja) | 抗ｃｘｃｒ４抗体および癌治療のためのそれらの使用 | |
| JP2023509196A5 (https=) | ||
| JP2017519759A5 (https=) | ||
| JP2009541492A5 (https=) | ||
| RU2014101669A (ru) | Агенты, связывающие белки r-спондины (rspo), и способы их применения | |
| CN116948035A (zh) | 多特异性抗体及其制备和使用方法 | |
| JP2021520201A5 (https=) | ||
| JP2022553922A5 (https=) | ||
| JP2019512207A5 (https=) | ||
| CN112292399A (zh) | 抗cd27抗体及其用途 | |
| CA3146986A1 (en) | Anti-tigit antibodies and application thereof | |
| JP2020502233A5 (https=) | ||
| JP2022526841A5 (https=) | ||
| US20230312742A1 (en) | CD38 antibodies for the treatment of human diseases | |
| WO2024113099A1 (en) | Protease cleavable recombinant bispecific antibodies and compositions and uses thereof | |
| JP2024533457A5 (https=) | ||
| JP2024517760A (ja) | 抗５ｔ４抗体及びその使用 | |
| AU2019306113B2 (en) | Anti-human PD-L1 antibodies and their uses | |
| JP2026506070A (ja) | 抗ｃｎｔｎ４抗体及びその使用 | |
| RU2024126025A (ru) | Антитела против msln и способы их применения | |
| HK40088417A (zh) | 多特异性抗体及其制备和使用方法 | |
| HK40093821A (zh) | 多特异性抗体及其制备和使用方法 |